Navigation Links
Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities
Date:3/17/2008

WOBURN, Massachusetts, March 17 /PRNewswire/ -- Mercury Therapeutics, Inc. (MTI), a company that discovers and develops orally active protein kinase targeted drugs, announces that it has retained Marquant Partners LLC (http://www.marquantpartners.com) to advise on its strategic and partnering opportunities, with the aim of maximizing value for MTI's shareholders.

This appointment follows a significant amount of interest that MTI has attracted from both financial and pharmaceutical companies after its announcement in November 2007 that it had made significant progress in its small molecule AMPK activator development program. Marquant is a specialist life sciences corporate finance boutique focused on advising privately held, small cap and emerging companies on licensing transactions, M&A, divestments, corporate strategy and company formation. Marquant's founders and principals are:

Dr. Pamela Joy Barton has over 12 years experience working with companies in the life sciences sector across the full spectrum of transactions - M&A, divestments, corporate partnering/licensing (inward and outward), IPOs and financings. Prior to Marquant, Joy's positions included: Vice President, Business Development at Nabi Biopharmaceuticals; Vice President, Business Development at Sosei Co. Ltd; Commercial Director at Xenova Group Limited; member of the Pharmaceuticals and Medical Products practice at Accenture; and various roles in the oncology therapeutic area with Novartis/Sandoz.

Dean Brown has over 14 years experience working as a transaction adviser to companies in the Life Sciences sector across the full spectrum of transactions - M&A, divestments, corporate partnering/licensing (inward and outward), and financings. Prior to Marquant, Dean spent almost 11 years as a partner with the Ferghana Partners Group, a boutique transaction advisory house operating in Europe and North America. During thi
'/>"/>

SOURCE Mercury Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
2. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
3. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
4. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
5. Nile Therapeutics, Inc. Adds to Executive Management Team
6. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
7. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
8. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
9. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
10. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
11. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 22, 2015 Protocol Networks brings independent ... team of brand-neutral, independent consultants, Protocol Networks has recently ... that over the years, his company has attracted several ... of Plainfield, as well as others. With the success ...
(Date:1/22/2015)... January 22, 2015 Controlled Substance Compliance ... which helps companies check the legal requirements around using ... to China. , As their international operations expand ... adopting software solutions built as a result of the ...
(Date:1/22/2015)...  Varian Medical Systems (NYSE: VAR ), world leader ... commitment to sustainability with inclusion on a prestigious list of ... healthcare equipment company among the Corporate Knights Global 100 Most ... at Davos, Switzerland . ...
(Date:12/24/2014)... and NEW YORK , Dec. 24, 2014 ... advancing patient care in critical areas, announced the closing of ... and warrants to purchase up to an aggregate 3,500,000 shares ... share and $.01 per warrant.  The warrants have a per ...
Breaking Biology Technology:Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Global Compliance Service for Controlled Substances to Expand to China 2Varian Honored Among World's 100 Most Sustainable Corporations 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... Board: SYMD), a biomaterials company engaged in the development,and ... Robert P. Hickey, President and CEO, will present at,the ... 2007 at,5:05 PM, EDT, at the New York Palace ... company overview. The presentation will be available via ...
... the Delft University of Technologys Kavli Institute of Nanoscience ... have succeeded in controlling the spin of a single ... way for a much simpler realization of the building ... will publish their work in Science Express on Thursday ...
... Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ), a biopharmaceutical ... medicines in the areas of hepatitis C and,oncology, ... quarter ended,September 30, 2007 and operational highlights. ... transition for Anadys,",said Steve Worland, Ph.D., President and ...
Cached Biology Technology:Delft University of Technology rotates electron spin with electric field 2Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 2Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 3Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 4Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 5Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 6Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 7Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 8Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights 9
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... the "The Global Watermarking and Fingerprinting Markets" ... http://photos.prnewswire.com/prnh/20130307/600769 This insight ... watermarking and fingerprinting markets. Watermarking aims to control ...
(Date:12/19/2014)... VEGAS , Dec. 18, 2014   LaunchKey , ... for the post-password and Internet of Things era, today ... funding. The venture round was led by Metamorphic Ventures ... Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey has raised ...
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has ... Market 2015-2019" report to their offering. ... trend upcoming in this market is the increasing demand ... in recording of patient data for quick and correct ...
Breaking Biology News(10 mins):The Global Watermarking and Fingerprinting Markets 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2
... May 30, 2011 Reportlinker.com announces that ... in its catalogue: Enzymes ... http://www.reportlinker.com/p0535955/Enzymes-in-Drug-Manufacturing.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical Biocatalysis in pharmaceutical ... enzyme and genomics technologies that are increasing ...
... Nature a new molecular pathway used to suppress blood ... potential therapeutic value for fighting diseases of the retina and ... blood cells involved in the immune system, use this molecular ... in the same study researchers were able to reverse this ...
... drugs to combat or cure human disease often involves a ... clearly into a living mouse,s innards has real value. ... interior of laboratory mice, the view becomes so murky several ... divining the future from the rodent,s entrails than they do ...
Cached Biology News:Reportlinker Adds Enzymes in Drug Manufacturing 2Reportlinker Adds Enzymes in Drug Manufacturing 3Reportlinker Adds Enzymes in Drug Manufacturing 4Reportlinker Adds Enzymes in Drug Manufacturing 5Reportlinker Adds Enzymes in Drug Manufacturing 6Novel pathway regulating angiogenesis may fight retinal disease, cancers 2Better viewing through fluorescent nanotubes when peering into innards of a mouse 2Better viewing through fluorescent nanotubes when peering into innards of a mouse 3
Antibody specific for trimethyl-Lys27 of histone H3. Mouse monoclonal. Antigen: Synthetic peptide derived from histone H3, trimethylated at lysine 27...
DL-Dithiothreitol (Clelands Reagent) ,PROTEASE FREE!! ,Molecular Biology Grade ,PRODUCT MUST SHIP NEXT DAY DURING HOT SUMMER MONTHS. ,C 4 H 10 O 2 S 2 ,Molecular Weight: 154.25 ,CAS RN: [27565-...
DTT 50 l...
...
Biology Products: